Higher prevalence of obesity and overweight without an adverse metabolic profile in girls with central precocious puberty compared to girls with early puberty, regardless of GnRH analogue treatment

Table 3 Three years evolution of GnRHa treated and untreated patients with EP

	Baseline		1 yr		2 yrs		3 yrs
	Treated	Untreated	Treated	Untreated	Treated	Untreated	Treated	Untreated	After Tx
CA (yr)	8.9 ± 0.6	8.8 ± 0.5	9.9 ± 0.6	9.8 ± 0.6	10.8 ± 0.7	10.7 ± 0.6	11.6 ± 0.7	11.5 ± 0.5	11.8 ± 0.4
Weight (z-score)	0.3 ± 0.7*	0.9 ± 0.6	0.1 ± 08*	0.9 ± 0.3	0.2 ± 0.9*	0.9 ± 0.4	0.1 ± 0.9*	0.9 ± 0.5**	-0.1 ± 1.1
BMI (z-score)	0.4 ± 0.7	0.9 ± 0.6	0.3 ± 0.8	0.8 ± 0.5	0.4 ± 0.9	0.7 ± 0.6	0.3 ± 1.2	0.8 ± 0.6	0 ± 0.8
Ob/over (%)	29	40	14	15	33	32	28.6	27	0
Obesity (%)	0	15	0	5	0	0	0	9	0
Overweight (%)	29	25	14	10	33	32	28.6	18	0
Glycemia (mg/dl)	79 ± 9.9	81.3 ± 11.1	89 ± 15.3	83.3 ± 9.7	84.3 ± 6.1	81.2 ± 8.6	84 ± 5.7	83 ± 6.4	83
Total-C (mg/dl)	195 ± 36.4	178.3 ± 35.5	184.8 ± 37.1	183.5 ± 33.8	186.8 ± 25	187.7 ± 41.8	133.5 ± 0.7	139.4 ± 37.6	123
LDL-C (mg/dl)	125 ± 38.4	113.2 ± 17.6	117.5 ± 42.8	131.5 ± 28.4	89.6 ± 66	105.8 ± 21.8	70.8 ± 5.1	83.7 ± 6.5	N.A
HDL-C (mg/dl)	50.6 ± 1.8	53 ± 9.1	51.3 ± 4.8	42.1 ± 7.4	47.7 ± 2.5	56 ± 24.3	49 ± 1.4	34.3 ± 4	N.A
TGR (mg/dl)	92.5 ± 30.9	113.4 ± 58.3	110 ± 43	73.9 ± 18	88 ± 18.5	85 ± 36	68.5 ± 14.9	96.5 ± 36.6	N.A.
TGR/HDL-C ratio	1.8 ± 0.6	1.5 ± 0.5	2.2 ± 1.3	1.9 ± 0.5	1.8 ± 0.3	1.5 ± 1	1.4 ± 0.3	2 ± 0.5	N.A.

Data are expressed as mean ± SDS. SDS denotes the standard-deviation score for age and sex.
After Tx, after treatment; CA, Chronological age; BMI, body mass index; Ob/Over, obesity and overweight rate; Total-C, total cholesterol; LDL-C, Low density lipoprotein cholesterol; HDL-C, High density lipoprotein cholesterol; TGR, Triglycerides.
*p <0.05 treated vs. untreated patients.
**p 0.03 untreated vs. patients after stop treatment.

ISSN: 1687-9856